Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Identifieur interne : 000399 ( Main/Exploration ); précédent : 000398; suivant : 000400Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Auteurs : Roberto Sorio [Italie] ; Célia Roemer-Becuwe [France] ; Felix Hilpert [Allemagne] ; Emma Gibbs [Australie] ; Yolanda García [Espagne] ; Janne Kaern [Norvège] ; Manon Huizing [Belgique] ; Petronella Witteveen [Pays-Bas] ; Flora Zagouri [Grèce] ; David Coeffic [France] ; Hans-Joachim Lück [Allemagne] ; Antonio González-Martín [Espagne] ; Gunnar Kristensen [Norvège] ; Charles-Briac Levaché [France] ; Chee Khoon Lee [Australie] ; Val Gebski [Australie] ; Eric Pujade-Lauraine [France]Source :
- Gynecologic oncology [ 1095-6859 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Bévacizumab (administration et posologie), Bévacizumab (effets indésirables), Composés du platine, Doxorubicine (administration et posologie), Doxorubicine (analogues et dérivés), Facteurs de l'âge, Femelle, Humains, Hypertension artérielle (), Hypertension artérielle (physiopathologie), Paclitaxel (administration et posologie), Polyéthylène glycols (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récidive tumorale locale (traitement médicamenteux), Résistance aux médicaments antinéoplasiques, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Sélection de patients, Topotécane (administration et posologie), Tumeurs de l'ovaire (traitement médicamenteux).
- MESH :
- administration et posologie : Bévacizumab, Doxorubicine, Paclitaxel, Polyéthylène glycols, Topotécane.
- analogues et dérivés : Doxorubicine.
- effets indésirables : Bévacizumab, Protocoles de polychimiothérapie antinéoplasique.
- physiopathologie : Hypertension artérielle.
- traitement médicamenteux : Récidive tumorale locale, Tumeurs de l'ovaire.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Composés du platine, Facteurs de l'âge, Femelle, Humains, Hypertension artérielle, Résistance aux médicaments antinéoplasiques, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Sélection de patients.
English descriptors
- KwdEn :
- Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bevacizumab (administration & dosage), Bevacizumab (adverse effects), Disease-Free Survival, Doxorubicin (administration & dosage), Doxorubicin (analogs & derivatives), Drug Resistance, Neoplasm, Female, Humans, Hypertension (chemically induced), Hypertension (physiopathology), Middle Aged, Neoplasm Recurrence, Local (drug therapy), Ovarian Neoplasms (drug therapy), Paclitaxel (administration & dosage), Patient Selection, Platinum Compounds, Polyethylene Glycols (administration & dosage), Topotecan (administration & dosage).
- MESH :
- chemical , administration & dosage : Bevacizumab, Doxorubicin, Paclitaxel, Polyethylene Glycols, Topotecan.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Bevacizumab.
- chemical , analogs & derivatives : Doxorubicin.
- chemically induced : Hypertension.
- drug therapy : Neoplasm Recurrence, Local, Ovarian Neoplasms.
- physiopathology : Hypertension.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Age Factors, Aged, Aged, 80 and over, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Middle Aged, Patient Selection, Platinum Compounds.
Abstract
The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC).
DOI: 10.1016/j.ygyno.2016.11.006
PubMed: 27871723
Affiliations:
- Allemagne, Australie, Belgique, Espagne, France, Grèce, Italie, Norvège, Pays-Bas
- Attique (région), Basse-Saxe, Catalogne, Communauté de Madrid, Grand Est, Hambourg, Lorraine (région), Nouvelle-Galles du Sud, Île-de-France
- Athènes, Barcelone, Hambourg, Hanovre, Madrid, Nancy, Paris, Sydney
- Université Paris-Descartes, Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001250
- to stream PubMed, to step Curation: 001239
- to stream PubMed, to step Checkpoint: 001239
- to stream Ncbi, to step Merge: 003F18
- to stream Ncbi, to step Curation: 003F18
- to stream Ncbi, to step Checkpoint: 003F18
- to stream Main, to step Merge: 000394
- to stream Main, to step Curation: 000399
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.</title><author><name sortKey="Sorio, Roberto" sort="Sorio, Roberto" uniqKey="Sorio R" first="Roberto" last="Sorio">Roberto Sorio</name><affiliation wicri:level="1"><nlm:affiliation>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN, Italy. Electronic address: rsorio@cro.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN</wicri:regionArea><wicri:noRegion>PN</wicri:noRegion></affiliation></author><author><name sortKey="Roemer Becuwe, Celia" sort="Roemer Becuwe, Celia" uniqKey="Roemer Becuwe C" first="Célia" last="Roemer-Becuwe">Célia Roemer-Becuwe</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy</wicri:regionArea><wicri:noRegion>54000 Nancy</wicri:noRegion><placeName><settlement type="city">Nancy</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name><affiliation wicri:level="1"><nlm:affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg</wicri:regionArea><wicri:noRegion>20357 Hamburg</wicri:noRegion><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Gibbs, Emma" sort="Gibbs, Emma" uniqKey="Gibbs E" first="Emma" last="Gibbs">Emma Gibbs</name><affiliation wicri:level="4"><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Garcia, Yolanda" sort="Garcia, Yolanda" uniqKey="Garcia Y" first="Yolanda" last="García">Yolanda García</name><affiliation wicri:level="3"><nlm:affiliation>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Kaern, Janne" sort="Kaern, Janne" uniqKey="Kaern J" first="Janne" last="Kaern">Janne Kaern</name><affiliation wicri:level="1"><nlm:affiliation>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo</wicri:regionArea><wicri:noRegion>N-0424 Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Huizing, Manon" sort="Huizing, Manon" uniqKey="Huizing M" first="Manon" last="Huizing">Manon Huizing</name><affiliation wicri:level="1"><nlm:affiliation>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem</wicri:regionArea><wicri:noRegion>2650 Edegem</wicri:noRegion></affiliation></author><author><name sortKey="Witteveen, Petronella" sort="Witteveen, Petronella" uniqKey="Witteveen P" first="Petronella" last="Witteveen">Petronella Witteveen</name><affiliation wicri:level="1"><nlm:affiliation>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht</wicri:regionArea><wicri:noRegion>3508 GA Utrecht</wicri:noRegion></affiliation></author><author><name sortKey="Zagouri, Flora" sort="Zagouri, Flora" uniqKey="Zagouri F" first="Flora" last="Zagouri">Flora Zagouri</name><affiliation wicri:level="1"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Coeffic, David" sort="Coeffic, David" uniqKey="Coeffic D" first="David" last="Coeffic">David Coeffic</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims</wicri:regionArea><wicri:noRegion>51100 Reims</wicri:noRegion><wicri:noRegion>51100 Reims</wicri:noRegion></affiliation></author><author><name sortKey="Luck, Hans Joachim" sort="Luck, Hans Joachim" uniqKey="Luck H" first="Hans-Joachim" last="Lück">Hans-Joachim Lück</name><affiliation wicri:level="3"><nlm:affiliation>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Gonzalez Martin, Antonio" sort="Gonzalez Martin, Antonio" uniqKey="Gonzalez Martin A" first="Antonio" last="González-Martín">Antonio González-Martín</name><affiliation wicri:level="1"><nlm:affiliation>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name><affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo</wicri:regionArea><wicri:noRegion>N-0424 Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Levache, Charles Briac" sort="Levache, Charles Briac" uniqKey="Levache C" first="Charles-Briac" last="Levaché">Charles-Briac Levaché</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux</wicri:regionArea><wicri:noRegion>24000 Périgueux</wicri:noRegion><wicri:noRegion>24000 Périgueux</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name><affiliation wicri:level="4"><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation wicri:level="4"><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="4"><nlm:affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris</wicri:regionArea><wicri:noRegion>75004 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27871723</idno><idno type="pmid">27871723</idno><idno type="doi">10.1016/j.ygyno.2016.11.006</idno><idno type="wicri:Area/PubMed/Corpus">001250</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001250</idno><idno type="wicri:Area/PubMed/Curation">001239</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001239</idno><idno type="wicri:Area/PubMed/Checkpoint">001239</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001239</idno><idno type="wicri:Area/Ncbi/Merge">003F18</idno><idno type="wicri:Area/Ncbi/Curation">003F18</idno><idno type="wicri:Area/Ncbi/Checkpoint">003F18</idno><idno type="wicri:Area/Main/Merge">000394</idno><idno type="wicri:Area/Main/Curation">000399</idno><idno type="wicri:Area/Main/Exploration">000399</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.</title><author><name sortKey="Sorio, Roberto" sort="Sorio, Roberto" uniqKey="Sorio R" first="Roberto" last="Sorio">Roberto Sorio</name><affiliation wicri:level="1"><nlm:affiliation>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN, Italy. Electronic address: rsorio@cro.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>MITO and Centro di Riferimento Oncologico, CRO-IRCCS, Via F. Gallini, 2 - 33081 Aviano, PN</wicri:regionArea><wicri:noRegion>PN</wicri:noRegion></affiliation></author><author><name sortKey="Roemer Becuwe, Celia" sort="Roemer Becuwe, Celia" uniqKey="Roemer Becuwe C" first="Célia" last="Roemer-Becuwe">Célia Roemer-Becuwe</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54000 Nancy</wicri:regionArea><wicri:noRegion>54000 Nancy</wicri:noRegion><placeName><settlement type="city">Nancy</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name><affiliation wicri:level="1"><nlm:affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, Moorkamp 2-6, 20357 Hamburg</wicri:regionArea><wicri:noRegion>20357 Hamburg</wicri:noRegion><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Gibbs, Emma" sort="Gibbs, Emma" uniqKey="Gibbs E" first="Emma" last="Gibbs">Emma Gibbs</name><affiliation wicri:level="4"><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Garcia, Yolanda" sort="Garcia, Yolanda" uniqKey="Garcia Y" first="Yolanda" last="García">Yolanda García</name><affiliation wicri:level="3"><nlm:affiliation>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>GEICO and Hospital Universitari Parc Taulí, Parc Taulí 1, 08208 Sabadell, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Kaern, Janne" sort="Kaern, Janne" uniqKey="Kaern J" first="Janne" last="Kaern">Janne Kaern</name><affiliation wicri:level="1"><nlm:affiliation>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>NSGO and Oslo University Hospital HF, Radiumhospitalet, Postboks 4950, Nydalen, N-0424 Oslo</wicri:regionArea><wicri:noRegion>N-0424 Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Huizing, Manon" sort="Huizing, Manon" uniqKey="Huizing M" first="Manon" last="Huizing">Manon Huizing</name><affiliation wicri:level="1"><nlm:affiliation>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>BGOG and Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2650 Edegem</wicri:regionArea><wicri:noRegion>2650 Edegem</wicri:noRegion></affiliation></author><author><name sortKey="Witteveen, Petronella" sort="Witteveen, Petronella" uniqKey="Witteveen P" first="Petronella" last="Witteveen">Petronella Witteveen</name><affiliation wicri:level="1"><nlm:affiliation>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>DGOG and University Medical Center Utrecht, F02.126, PO Box 85500, 3508 GA Utrecht</wicri:regionArea><wicri:noRegion>3508 GA Utrecht</wicri:noRegion></affiliation></author><author><name sortKey="Zagouri, Flora" sort="Zagouri, Flora" uniqKey="Zagouri F" first="Flora" last="Zagouri">Flora Zagouri</name><affiliation wicri:level="1"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, Medical School, University of Athens, 133, Vas Sofias Av, 11528 Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Coeffic, David" sort="Coeffic, David" uniqKey="Coeffic D" first="David" last="Coeffic">David Coeffic</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Polyclinique Courlancy, 38 rue de Courlancy, 51100 Reims</wicri:regionArea><wicri:noRegion>51100 Reims</wicri:noRegion><wicri:noRegion>51100 Reims</wicri:noRegion></affiliation></author><author><name sortKey="Luck, Hans Joachim" sort="Luck, Hans Joachim" uniqKey="Luck H" first="Hans-Joachim" last="Lück">Hans-Joachim Lück</name><affiliation wicri:level="3"><nlm:affiliation>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, D30177 Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Gonzalez Martin, Antonio" sort="Gonzalez Martin, Antonio" uniqKey="Gonzalez Martin A" first="Antonio" last="González-Martín">Antonio González-Martín</name><affiliation wicri:level="1"><nlm:affiliation>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>GEICO and MD Anderson Cancer Center Spain, C/Arturo Soria 270, 28033 Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name><affiliation wicri:level="1"><nlm:affiliation>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>NSGO and Department of Gynecological Cancer and Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital and Institute for Clinical Medicine, Oslo University, Postboks 4950, Nydalen, N-0424 Oslo</wicri:regionArea><wicri:noRegion>N-0424 Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Levache, Charles Briac" sort="Levache, Charles Briac" uniqKey="Levache C" first="Charles-Briac" last="Levaché">Charles-Briac Levaché</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Clinique Francheville, 38 Boulevard de Vésone, BP 4063, 24000 Périgueux</wicri:regionArea><wicri:noRegion>24000 Périgueux</wicri:noRegion><wicri:noRegion>24000 Périgueux</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name><affiliation wicri:level="4"><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation wicri:level="4"><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="4"><nlm:affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu - Oncologie, 1 Place du Parvis Notre-Dame - Place Jean-Paul II, 75004 Paris</wicri:regionArea><wicri:noRegion>75004 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author></analytic><series><title level="j">Gynecologic oncology</title><idno type="eISSN">1095-6859</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bevacizumab (administration & dosage)</term><term>Bevacizumab (adverse effects)</term><term>Disease-Free Survival</term><term>Doxorubicin (administration & dosage)</term><term>Doxorubicin (analogs & derivatives)</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Hypertension (chemically induced)</term><term>Hypertension (physiopathology)</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Ovarian Neoplasms (drug therapy)</term><term>Paclitaxel (administration & dosage)</term><term>Patient Selection</term><term>Platinum Compounds</term><term>Polyethylene Glycols (administration & dosage)</term><term>Topotecan (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bévacizumab (administration et posologie)</term><term>Bévacizumab (effets indésirables)</term><term>Composés du platine</term><term>Doxorubicine (administration et posologie)</term><term>Doxorubicine (analogues et dérivés)</term><term>Facteurs de l'âge</term><term>Femelle</term><term>Humains</term><term>Hypertension artérielle ()</term><term>Hypertension artérielle (physiopathologie)</term><term>Paclitaxel (administration et posologie)</term><term>Polyéthylène glycols (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Récidive tumorale locale (traitement médicamenteux)</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Sélection de patients</term><term>Topotécane (administration et posologie)</term><term>Tumeurs de l'ovaire (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bevacizumab</term><term>Doxorubicin</term><term>Paclitaxel</term><term>Polyethylene Glycols</term><term>Topotecan</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Bévacizumab</term><term>Doxorubicine</term><term>Paclitaxel</term><term>Polyéthylène glycols</term><term>Topotécane</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Bevacizumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Doxorubicin</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Doxorubicine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Bévacizumab</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hypertension artérielle</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Récidive tumorale locale</term><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Patient Selection</term><term>Platinum Compounds</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Composés du platine</term><term>Facteurs de l'âge</term><term>Femelle</term><term>Humains</term><term>Hypertension artérielle</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Sélection de patients</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC).</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Italie</li><li>Norvège</li><li>Pays-Bas</li></country><region><li>Attique (région)</li><li>Basse-Saxe</li><li>Catalogne</li><li>Communauté de Madrid</li><li>Grand Est</li><li>Hambourg</li><li>Lorraine (région)</li><li>Nouvelle-Galles du Sud</li><li>Île-de-France</li></region><settlement><li>Athènes</li><li>Barcelone</li><li>Hambourg</li><li>Hanovre</li><li>Madrid</li><li>Nancy</li><li>Paris</li><li>Sydney</li></settlement><orgName><li>Université Paris-Descartes</li><li>Université de Sydney</li></orgName></list><tree><country name="Italie"><noRegion><name sortKey="Sorio, Roberto" sort="Sorio, Roberto" uniqKey="Sorio R" first="Roberto" last="Sorio">Roberto Sorio</name></noRegion></country><country name="France"><region name="Grand Est"><name sortKey="Roemer Becuwe, Celia" sort="Roemer Becuwe, Celia" uniqKey="Roemer Becuwe C" first="Célia" last="Roemer-Becuwe">Célia Roemer-Becuwe</name></region><name sortKey="Coeffic, David" sort="Coeffic, David" uniqKey="Coeffic D" first="David" last="Coeffic">David Coeffic</name><name sortKey="Levache, Charles Briac" sort="Levache, Charles Briac" uniqKey="Levache C" first="Charles-Briac" last="Levaché">Charles-Briac Levaché</name><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name></country><country name="Allemagne"><region name="Hambourg"><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name></region><name sortKey="Luck, Hans Joachim" sort="Luck, Hans Joachim" uniqKey="Luck H" first="Hans-Joachim" last="Lück">Hans-Joachim Lück</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Gibbs, Emma" sort="Gibbs, Emma" uniqKey="Gibbs E" first="Emma" last="Gibbs">Emma Gibbs</name></region><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Garcia, Yolanda" sort="Garcia, Yolanda" uniqKey="Garcia Y" first="Yolanda" last="García">Yolanda García</name></region><name sortKey="Gonzalez Martin, Antonio" sort="Gonzalez Martin, Antonio" uniqKey="Gonzalez Martin A" first="Antonio" last="González-Martín">Antonio González-Martín</name></country><country name="Norvège"><noRegion><name sortKey="Kaern, Janne" sort="Kaern, Janne" uniqKey="Kaern J" first="Janne" last="Kaern">Janne Kaern</name></noRegion><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name></country><country name="Belgique"><noRegion><name sortKey="Huizing, Manon" sort="Huizing, Manon" uniqKey="Huizing M" first="Manon" last="Huizing">Manon Huizing</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Witteveen, Petronella" sort="Witteveen, Petronella" uniqKey="Witteveen P" first="Petronella" last="Witteveen">Petronella Witteveen</name></noRegion></country><country name="Grèce"><region name="Attique (région)"><name sortKey="Zagouri, Flora" sort="Zagouri, Flora" uniqKey="Zagouri F" first="Flora" last="Zagouri">Flora Zagouri</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000399 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000399 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27871723
|texte= Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27871723" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |